NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$2.65 | -$0.99 | Beat |
| May 14, 2026 | -$2.64 | -$1.25 | Beat |
| Mar 19, 2026 | -$2.69 | -$1.47 | Beat |
| Nov 13, 2025 | -$2.69 | -$0.10 | Beat |
| Aug 20, 2025 | -$2.75 | -$0.16 | Beat |
| Jun 3, 2025 | -$0.01 | -$5.17 | Miss |